Regulatory news and analysis for GRAS teams.

GRN 1310 is a useful recent signal for teams working with high-intensity sweeteners, steviol glycosides, and enzymatic production processes. FDA lists the notice as rebaudioside M produced by enzymatic treatment of rebaudioside A purified from Stevia rebaudiana leaves, with the notifier identifying the basis as scientific procedures.

The intended use is broad but bounded: a general-purpose sweetener in foods, excluding infant formula and products under U.S. Department of Agriculture jurisdiction, at levels determined by current good manufacturing practice. That combination of identity, manufacturing route, use scope, and exposure framing is exactly the kind of structure GRAS teams need to keep tight before external review.

FDA closed the notice on July 6, 2026 with a no-questions letter. For sponsors, the practical takeaway is not that every steviol glycoside or enzyme-mediated production process is interchangeable. It is that the agency continues to evaluate the full dossier record: source material, manufacturing controls, specifications, intended conditions of use, estimated dietary exposure, and the safety basis supporting the GRAS conclusion.

In GRAS work, the most important early question is rarely whether a document can be drafted. The more consequential question is whether the dossier logic can withstand systematic review. Decision-tree systems help make that review explicit by forcing teams to test identity, manufacturing, exposure, specifications, and safety support against defined checkpoints.

For FDA-facing work, this matters because a no-questions outcome depends on the coherence of the record, not merely the presence of citations. A well-designed decision tree can expose where the submission basis is scientific-procedure GRAS rather than common-use GRAS, where intended conditions of use are too broad, where exposure assumptions are not yet defensible, and where a safety narrative has not connected the underlying data to the proposed use.

The best systems are not generic checklists. They are section-aware, evidence-sensitive, and traceable. They preserve the reasoning path that led to a readiness conclusion and make it easier for regulatory, scientific, and legal reviewers to identify the precise point at which additional support is required.

Under the U.S. food safety framework, a substance may be excluded from the food additive approval requirement when its safety is generally recognized among qualified experts under the intended conditions of use. FDA's voluntary GRAS notification program gives companies a pathway to submit a notice and receive a response letter, including the familiar outcome that FDA has no questions regarding the notifier's GRAS conclusion.

That framework is distinct from mandatory premarket food additive approval. FDA has explained that a GRAS conclusion can be made by qualified experts outside government, while the agency's notification program provides a mechanism for review of the submitted basis. The result is a system that has historically allowed both notified GRAS conclusions and self-affirmed GRAS conclusions that are not submitted to FDA.

The current policy environment is changing. In March 2025, HHS directed FDA to explore potential rulemaking to revise the GRAS final rule and related guidance, specifically targeting the self-affirmed pathway. As of this writing, the core practical takeaway is not that every self-affirmed GRAS conclusion has disappeared, but that sponsors should expect increased pressure for stronger records, clearer expert rationale, and better readiness for regulatory scrutiny.